People who suspect they may have COVID-19 could soon find out with a simple breath test that delivers results in three minutes.
The U.S. Food and Drug Administration granted an emergency use authorization for a device called the InspectIR Covid-19 Breathalyzer.
RELATED: Medicare Now Covers COVID Tests Bought at Drug Stores
With a single-use sanitary paper straw people blow their breath sample, about the amount it takes “to inflate a small balloon,” into the system, according to the company, which looks for the chemistry and compounds associated with COVID-19.
The test, which must be administered by a trained operator, demonstrates a high degree of accuracy while taking up no more space than a piece of carry-on luggage.
“Today’s authorization is yet another example of the rapid innovation occurring with diagnostic tests for COVID-19,” Dr. Jeff Shuren, director of the FDA’s Center for Devices and Radiological Health, said in an agency news release announcing the approval. “The FDA continues to support the development of novel COVID-19 tests with the goal of advancing technologies that can help address the current pandemic and better position the U.S. for the next public health emergency.”
InspectIR can run 160 samples per day and may be used at mobile testing sites, hospitals and doctors’ offices. The company can produce about 100 of the machines a week, according to The New York Times.
The test uses gas chromatography gas mass-spectrometry, a technique that separates and identifies chemical mixtures, to spot the presence of five compounds associated with the coronavirus.
The company anticipates leasing test devices to companies and within industries ideal for en masse screening such as
nursing homes, prisons and the travel and hospitality industry, such as cruise lines, and perhaps schools. The company expects leasing agreements to cost between $25,000 and $30,000 per month.
The dollar amount sounds large, but the company hopes to get the cost per test down to an average of $10 to $12 each, according to InspectIR Systems COO John Redmond. This is in line with (maybe even cheaper than) commercially available at-home rapid tests. The leasing price would include a supply of individually wrapped paper straws, an air filter for the test kit and other necessary components.
Its accuracy was confirmed in a large study of just over 2,400 people, including those with and without symptoms. In the end, the test was shown to have 91.2% sensitivity (the percent of positive samples the test correctly identified) and 99.3% specificity (the percent of negative samples the test correctly identified). The test performed just as well in a follow-up study focused on the Omicron variant.
The test’s approval arrives as the Omicron subvariant BA.2 takes over the country, now accounting for almost 86% of all COVID cases, according to data from the U.S. Centers of Disease Control and Prevention. Several northeastern cities have seen cases climb recently as the subvariant surges, and Philadelphia even brought back its indoor mask mandate this week to try to stem the spread of BA.2.
RELATED: CDC Extends Mask Mandate on Planes, Trains to May 3
A positive test should be confirmed through another testing method, such as a PCR lab test, the FDA stresses.
The agency warns that negative tests “should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19” and “should not be used as the sole basis for treatment or patient management decisions, including infection control decisions.”
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
